

For Immediate Release

Bangalore, India

October 22, 2009

Biocon Limited Announces Results for the Half-Year Ended September 30, 2009

Revenues rise to Rs 1,098 crores; EBITDA at Rs 236 crores; PAT at Rs 132 crores.

“Our numbers tell our compelling story. MTM losses are behind us. We have delivered strong earnings in the first half and are confident of sustaining this performance for the remainder of the year”, said Chairman and Managing Director, Biocon Group, Ms. Kiran Mazumdar-Shaw.

Performance Highlights

For Half-Year ended September 30, 2009

Biocon Group including German Subsidiary AxiCorp

- Total Income at Rs 1098 crores. Up 50% YoY.
- EBITDA at Rs 236 crores. YoY growth was 40%.
- PAT at Rs 132 crores. YoY growth was 230% (up 32% YoY pre-exceptionals).
- Operating Margin at 22%.
- Earnings Per Share at Rs 6.82.

Biocon Group excluding German Subsidiary AxiCorp

- Total Income at Rs 696 crores. Up 17% YoY.
- EBITDA at Rs 213 crores. YoY growth was 31%.
- PAT at Rs 121 crores. Up 218% YoY (up 24% YoY pre-exceptionals).
- Operating Margin at 31%.

For three months ended September 30, 2009

Biocon Group including German Subsidiary AxiCorp.

- Total Income at Rs 592 crores. Up 29% YoY.
- EBITDA at Rs 125 crores. YoY growth was 41%.
- PAT at Rs 74 crores. YoY growth was 192% (up 47% YoY pre-exceptionals).
- Operating Margin at 21%.
- Earnings Per Share at Rs 3.84.

Biocon Group excluding German Subsidiary AxiCorp

- Total Income at Rs 379 crores. YoY growth was 20%.
- EBITDA at Rs 114 crores. YoY growth was 37%.
- PAT at Rs 69 crores. YoY growth was 190%.
- Operating Margin at 30%.

Discussion of Business Operations

CMD, Biocon Group, Ms. Kiran Mazumdar-Shaw comments on -

- **Q2FY10 Syngene and Clinigene performance-** “Both Syngene and Clinigene have posted strong results and we believe that our investments are delivering good returns. The operations are strong and the investments made thus far assure good future profitability”.

- **Biocon's agreement to acquire Hyderabad-based bulk manufacturer IDL Specialty** - "We chose an inorganic path in preference to green field expansion, owing to significant advantages in time-to-market, shorter payback on investment and other commercials. The plan is to expand our chemical synthesis capabilities and manufacture advanced intermediates in this new facility. This additional capacity will enable us to address certain API opportunities in a timely manner."
- **Biocon pact with California-based Amylin Pharmaceuticals for peptide therapeutics** - "Our partnership with Amylin is primarily synergy driven. Biocon will bring its recombinant DNA technology, large-scale manufacturing and low-cost pre-clinical and clinical development capabilities to the partnership while Amylin, a front-runner in peptide therapeutics will bring in its proprietary "phybrid" technology and other key development capabilities. The trend today in the Biotech business world is one of "profit together". Given that it takes a minimum of 5-7 years and approximately \$1.2 bn to bring a drug into the market, collaborative co-development models are the new paradigms as it allows each partner to leverage each other's capabilities, share the risks as well as R&D costs and scale up quickly."
- **German subsidiary AxiCorp's performance** - "AxiCorp continues to grow robustly. It is a profitable, revenue-driven business that is largely accretive to our top line as of now. AxiCorp is ranked amongst the fastest growing pharmaceutical companies in Germany. Biocon and AxiCorp are on track with the regulatory process for the registration of Recombinant Human Insulin with EMEA. "
- **Innovation progress** - "We have made significant progress in our R&D efforts and are pleased with the progress made. Our Oral Insulin program, IN 105, expects to complete patient enrollment in Q3 this fiscal. We expect to report Phase III data by the end of Q1 FY2011. T1h, our other leading research program, has shown promising Phase II data in Rheumatoid Arthritis (RA) as well as Psoriasis. We plan to commence Phase III trials for Psoriasis by the end of this calendar year and Phase III for RA in the next calendar year." On Biosimilars, she said, "Our recently announced partnership with Mylan for biosimilars is on track with both partners aiming to secure a market leader position in the biosimilar space. This partnership is based on complementary capabilities and shared costs wherein we expect paybacks to commence within three years starting with emerging markets. Much larger returns are expected post 2014 once the regulated markets open up."

Business Outlook

On the outlook for the remainder of this fiscal, Ms. Mazumdar-Shaw said, "We are very pleased that our company has posted such strong growth. Even more exciting is the progress of our research pipeline. We believe we can sustain the current trend across all our businesses and are confident of delivering a strong performance for the full year. With respect to our business strategy, Biocon will always look at moving up the innovation value chain which we firmly believe will deliver sustainable growth for us. We forecast strong organic growth going forward but will also remain open to inorganic growth opportunities when they present themselves at the right price".

Below are comments from Ms. Kiran Mazumdar-Shaw on

- **Subsidiaries and Segments**- "Syngene and Clinigene have posted a strong quarter on the back of stronger relationships with key customers. We believe that the propeller for this growth is Syngene's ability to run a program right from discovery all the way to pre-clinical development for both small and large molecules. There is also the opportunity to take this to the clinic seamlessly through our CRO, Clinigene. We believe that our research services business is well differentiated in the market, given the end-to-end services we offer our growing customer base both in the development of small molecules as well as biologics. The Clinical Research Outsourcing space is enormous in terms of opportunities. Consultancy firm KPMG has estimated that this market is projected to hit US \$23 billion by 2011 and further that India will account for 15% of this (or roughly \$3.4 bn) by 2015. Importantly, these projections signify the growing interest of global pharma companies in conducting clinical trials in the emerging markets and also the value-per-dollar that these markets render vis-à-vis the developed world. Among these countries, India scores top of the list owing to its good IP track record and its highly-skilled scientific human capital with excellent communication skills."
- **Innovation Plans** - "Oral insulin is a global blockbuster market opportunity for Biocon. Based on the outcome of the Phase III trials, we will pursue a go-to-market strategy of launching in India first. We expect to realize a large licensing opportunity for Biocon with this molecule. T1h will shortly enter phase III trials for Psoriasis and we expect to initiate

licensing discussions for this over the next 12 months. Phase III for Rheumatoid Arthritis will commence in the next calendar year. With respect to our immuno-conjugates program with IATRICa, we expect to file the IND by Q2 FY2011”.

“Biocon has systematically built its bio-pharmaceutical business on a framework of generic and proprietary products and processes. We are steadily gaining global manufacturing scale and have increased our footprint in many world markets. Our demonstrated expertise in both small molecules and biologics has enabled us to build key partnerships across our businesses. Our bet on innovation is already delivering long-term value creation. We are now at a stage of post-gestational growth, which we expect will deliver sustained shareholder value for the foreseeable future” - CMD, Biocon Group, Ms. Kiran Mazumdar-Shaw.

Corporate Developments

Biocon in pact to acquire Hyderabad firm IDL Specialty Chemicals Limited - Biocon Limited announced on September 30 that it had signed a definitive agreement to acquire Hyderabad-based chemical synthesis unit IDL Specialty Chemicals Limited. Bulk manufacturer IDL is expected to add to Biocon’s existing capacity as well as help augment its product offerings in the chemical synthesis segment. The acquisition is subject to closing conditions detailed in the agreement.

Biocon inks pact with Amylin for diabetic segment - Biocon announced on September 12 that it had inked an exclusive co-development and marketing pact with California-based Amylin Pharmaceuticals for peptide therapeutics. Specifically, this will be geared towards a peptide hybrid or “phybrid” which will combine the properties of two peptides into one small molecule to treat diabetes. “As opposed to using single properties on its own, this technology is likely to give a differentiated clinical outcome by enabling the interplay of two peptides with dual benefits like lower sugar level and weight loss”, explained Biocon COO, Dr. Arun Chandavarkar. Amylin Pharmaceuticals has been a front-runner in the field of peptide therapeutics and is a leader in the diabetes market. For its part, Biocon will bring its recombinant DNA technology, large-scale manufacturing and low-cost pre-clinical and clinical development capabilities to this partnership. “Right now, the deal is a co-development deal which largely means that both Amylin and Biocon share the cost of development going forward. It is also a deal where we have marked out commercialization territory. Amylin would have the commercialization rights in North America, Biocon in most parts of Asia, and in the rest of the world, we will share the commercialization rights jointly,” said Dr. Chandavarkar. The two companies will share the development costs, a significant portion of which will arise in the phase III trials. Even as Amylin will own the intellectual property (IP) rights to the molecule and the “phybrid” technology, Biocon will hold the IP for the manufacturing. “Going forward, after assessing the synergies that may accrue to the companies, we could also broaden our collaboration”, he said.

Biocon among 20 Indian companies in Forbes 'Best Under A Billion' list - Biocon Ltd was included in the prestigious 'Best Under A Billion' list put out by Forbes this quarter. Only 20 Indian companies featured in the list this year. According to Forbes, the selected companies had grown sales and profits over the past 12 months or were forecast to do so in the coming quarters. This year’s list was dominated by companies that had withstood challenges that threatened their survival and those that had demonstrated exemplary entrepreneurship.

About Biocon

Established in 1978, Biocon Limited (**BSE code:** 532523, **NSE Id:** BIOCON, **ISIN Id:** INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMEA acceptance. Biocon’s robust product offering includes the world’s first recombinant human insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM). **For more information, visit www.biocon.com**

Disclaimer

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Earnings Call

The company will conduct an hour long call at 3 pm IST on Oct 22, 2009 where the senior management will discuss the company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The dial-in numbers for the call are 1800 425 4061/1800 425 4250/1800 22 4061 and 1800 425 1300 (accessible only through BSNL/MTNL Landlines). Other toll numbers are listed in the conference call invite which is posted on the company website www.biocon.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available from Oct 22, 2009 – October 29, 2009 on the same dial-in numbers provided above. The transcript of the conference call will also be put up on the company website.

Contact Information

Investor Relations	Jill Deviprasad +91 80 2808 2054 Jill.deviprasad@biocon.com
Media Relations	Paula Sengupta +91 80 2808 2808 Paula.sengupta@biocon.com

Encl: Fact Sheet - Consolidated Income Statement and Balance Sheet (Indian GAAP)

(All figures in Rs Crores, except EPS data)

Note: The discussions in this release reflect the financial performance of Biocon Limited and its subsidiaries based on Indian GAAP on a consolidated basis. Results for the German subsidiary are reported with a one-quarter lag.

BIOCON GROUP

**H1 FY 2010 vs H1 FY 2009
Q2 FY 2010 vs Q2 FY 2009**

FACT SHEET

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars							Full year ended	Full year ended
	H1	H1	Variance	H1	H1	Variance	Mar 31, 2009	Mar 31, 2009
	WITH AXICORP FY 10	WITH AXICORP FY 09		WITHOUT AXICORP FY 10	WITHOUT AXICORP FY 09		WITH AXICORP FY 2009	WITHOUT AXICORP FY 2009
<u>INCOME</u>								
Biopharmaceuticals	939	610	54%	539	471	14%	1,384	915
Contract research	137	96	43%	137	96	43%	225	225
Total Sales	1,076	706	52%	676	567	19%	1,609	1,139
Other income	22	28	-22%	20	27	-25%	65	54
Total Income / Revenues	1,098	734	50%	696	593	17%	1,673	1,194
<u>EXPENDITURE</u>								
Material & Power Costs	637	393	62%	313	279	12%	908	516
Staff costs	110	74	47%	77	64	20%	165	129
Research & Development	41	26	57%	41	26	57%	60	60
Forex Loss/ (gain)	8	10	-17%	8	10	-17%	11	11
Other Expenses	66	63	5%	43	52	-17%	141	107
Manufacturing, staff & other exps	862	566	52%	483	431	12%	1,285	822
PBDIT /EBIDTA	236	168	40%	213	162	31%	388	372
Interest and finance charges	11	8	38%	10	7	36%	18	15
PBDT	225	160	41%	204	155	31%	370	356
Depreciation	68	54	24%	65	52	26%	110	108
PBT	158	106	49%	138	103	34%	260	248
Current taxes	19	8	131%	13	8	55%	12	10
Deferred taxes	4	(1)		4	(1)		0	0
Taxes	23	8	204%	17	8	121%	12	10
PROFIT FOR THE PERIOD	135	98	37%	121	96	27%	248	238
Add/(less): Minority interest / Share of Losses in Associates	(3)	2	-281%	-	2	0%	(8)	(5)
Profit before Exceptional Items	132	100	32%	121	98	24%	240	234
Exceptional Item (MTM Provision - Forex) - Net of tax	0	(60)	-100%	0	(60)	0%	(147)	(147)
NET PROFIT (PAT)	132	40	230%	121	38	218%	93	87
EPS on issued capital Rs. (before exceptional items)	7	5		6	5		12	12

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceutical sales includes licensing income of Rs 12.6 crores for H1 FY2010 and Rs 3 crores for H1 FY2009 (both with and without AxiCorp)

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q2	Q2	Variance	Q2	Q2	Variance	Full year ended	Full year ended
	WITH	WITH		WITHOUT	WITHOUT		Mar 31, 2009	Mar 31, 2009
	AXICORP	AXICORP		AXICORP	AXICORP		WITH	WITHOUT
	FY 10	FY 09		FY 10	FY 09		FY 2009	FY 2009
<u>INCOME</u>								
Biopharmaceuticals	507	389	30%	294	250	18%	1,384	915
Contract research	73	53	37%	73	53	37%	225	225
Total Sales	580	442	31%	367	303	21%	1,609	1,139
Other income	12	15	-19%	12	14	-14%	65	54
Total Income / Revenues	592	458	29%	379	317	20%	1,673	1,194
<u>EXPENDITURE</u>								
Material & Power Costs	348	257	35%	177	144	23%	908	516
Staff costs	57	43	32%	39	33	20%	165	129
Research & Development	21	15	36%	21	15	36%	60	60
Forex Loss/ (gain)	(5)	12	-143%	(6)	12	-146%	11	11
Other Expenses	47	41	14%	35	30	15%	141	107
Manufacturing, staff & other exps	467	369	27%	266	234	14%	1,285	822
PBDIT /EBIDTA	126	89	41%	114	83	37%	388	372
Interest and finance charges	5	4	24%	5	4	34%	18	15
PBDT	120	85	42%	109	80	37%	370	356
Depreciation	35	29	21%	34	27	28%	110	108
PBT	85	56	53%	75	53	41%	260	248
Current taxes	10	5	89%	7	5	27%	12	10
Deferred taxes	(1)	1	-220%	(1)	1		0	0
Taxes	9	6	62%	6	6	5%	12	10
PROFIT FOR THE PERIOD	76	50	52%	69	47	45%	248	238
Add/(less): Minority interest / Share of Losses in Associates	(2)	1	-383%	0	1	0%	(8)	(5)
Profit before Exceptional Items	74	50	47%	69	49	41%	240	234
Exceptional Item (MTM Provision - Forex) - Net of tax	0	(25)	-100%	0	(25)	0%	(147)	(147)
NET PROFIT (PAT)	74	25	192%	69	24	190%	93	87
EPS on issued capital Rs. (before exceptional items)	4	3		3	2		12	12

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 10.6 crores in Q2 FY2010, Rs 3 crores in Q2 FY2009 (both with and without Axicorp);

BIOCON LIMITED (CONSOLIDATED) UNAUDITED**BALANCE SHEET***(Rs. Crores)*

Particulars	As at 30-Sep-09	As at 31-Mar-09
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	1,545	1,411
Total Shareholder's Funds	1,645	1,511
Minority interest	28	25
Deferred Tax Liability	51	47
Secured Loans	298	396
Unsecured Loans	131	128
Total Loan Funds	429	524
Total	2,153	2,106
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,199	1,221
Intangible Assets	173	163
Investments	318	368
Inventories	375	319
Sundry debtors	421	367
Cash and bank balances	49	12
Loans and advances	110	95
Total Current Assets, Loans & Advances	954	792
Less: Current liabilities and provisions	491	438
Net Current assets	463	355
Total	2,153	2,106



Press Release - 2

Kiran Mazumdar Shaw in Financial Times' 'Top 50 women in business' list

Bangalore September 29, 2009. Kiran Mazumdar Shaw, CMD, Biocon Ltd, India's leading biotechnology major, has been included in the prestigious 'Top 50 women in business' listing by Financial Times, London. The report, compiled in collaboration with recruitment group Egon Zehnder International, celebrates women business leaders around the world and this year's list features three Indians.

FT used a range of factors to assess the candidates including biographical information, data on the size of the company (turnover and number of employees), its scope and complexity (operations in multiple countries or sectors) and the competitive landscape. Total shareholder return was also used to gauge corporate performance. This varied according to the country, sector and characteristics of the company. Women running companies with a multinational reach were likely to rank more highly than those in charge of nationally focused groups.

The number of women business leaders around the world remains miniscule. Just 3 per cent of Fortune 500 chief executives are women. Across Europe, only 10 per cent of board directors of the largest companies are female (quotas have made Norway the exception, with more than 40 per cent) and the numbers are even lower in Asia. There is substantial evidence that better gender balance has a positive impact on performance. Studies by Catalyst and McKinsey in the US and Europe have found a correlation between the number of women in a company's leadership and the company's profitability.



About Biocon Limited

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Together with its group companies, Biocon forms a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research which deliver products and solutions to partners and customers across the globe. Biocon launched the world's first recombinant human insulin, INSUGEN[®] in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR[™].

A leading US trade publication, Med Ad News, in its 2007/08 listings has ranked Biocon 20th amongst the leading biotechnology companies in the world and the 7th largest Biotech employer in the world. Biocon recently received the 2009 BioSingapore Asia Pacific Biotechnology Award for Best Listed Company.

Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, Biocon offers novel therapies on a platform of affordable innovation. Biocon's strategic licensing partnerships provide market penetration and global access to deliver breakthrough therapeutics to millions of patients the world over.

Visit us at www.biocon.com

For further information contact:

Paula Sengupta

Biocon Limited

Tel: +91 80 2808 2808

Fax: +91 80 2852 3423

Email: paula.sengupta@biocon.com

Sonia Sharma

Brodeur India

Tel: +91 80 4042 9047

Fax: +91 80 4042 9100

Email: ssharma@brodeurindia.com



Press Release - 3

Biocon among 20 Indian companies in Forbes 'Best Under A Billion' list

Bangalore Sep 23, 2009. Biocon Ltd, India's leading biotechnology major, has been included in the prestigious 'Best Under A Billion' listing by Forbes. This year, only 20 Indian companies have been featured in the list, which is dominated by companies from Greater China. "All have either increased sales and profits over the past 12 months or are forecast to do so in coming quarters. Apparel, media, technology and health care led the way." said Forbes. This year's list is dominated by companies that have withstood challenges that threatened their survival and those that have demonstrated exemplary entrepreneurship.

For the fifth annual "Best under a Billion" list, the top 200 companies were picked from over 12,000 publicly-listed firms with sales of less than \$1 billion in the Asia-Pacific region. The list was mainly dominated by as many as 78 small and mid-sized firms from China and Hong Kong due to the relative economic prosperity of these regions. Japan was the second most represented country in the coveted list with 24 companies, while its neighbour South Korea had 23 firms. India was ranked at the fourth place with 20 entries, followed by Australia with 18.

As many as 64 of the entries on this year's list are returnees — "a testament to fearless management" Forbes said, while 136 are new entries —who have "seized opportunities arising from economic uncertainty".



COMPANY/industry	SALES latest 12 mo (\$mil)	NET INCOME latest 12 mo (\$mil)	MARKET VALUE (\$mil)	RETURN ON EQUITY 5-year average %
INDIA				
AIA Engineering / industrial equipment	201	34	500	26
Allied Digital Services / IT outsourcing	74	11	164	49
AurionPro Solutions / computer software	54	8	61	26
Bang Overseas / textiles	36	3	19	41
Biocon / biotech research	317	47	875	26
Birla / construction materials	351	64	456	38
Deepak Fertilisers & Petrochem / ag chemicals	292	27	145	15
Divi's Laboratories / drug ingredients	233	82	1,273	35
Everest Kanto Cylinder / gas storage products	169	27	384	33
FDC / pharmaceuticals	116	17	164	26
Geodesic / publishing	127	56	240	35
GSS America Infotech / IT software	74	16	47	221
ICSA / IT consulting	168	28	158	45
IVRCL Infrastructure & Projects / construction svcs	957	71	954	18
Micro Technologies / IT consulting	57	14	29	28
Nitin Fire Protection Industries / security systems	33	5	88	35
Opto Circuits / medical devices	161	41	607	49
Parekh Aluminex / aluminum foil	83	8	26	21
Raj Television Network / TV broadcasting	13	3	13	10
Selan Exploration Technology / oil exploration	20	9	66	27

About Biocon Limited

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Together with its group companies, Biocon forms a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research which deliver products and solutions to partners and customers across the globe. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™.

A leading US trade publication, Med Ad News, in its 2007/08 listings has ranked Biocon 20th amongst the leading biotechnology companies in the world and the 7th largest Biotech employer in the world. Biocon recently received the 2009 BioSingapore Asia Pacific Biotechnology Award for Best Listed Company.

Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, Biocon offers novel therapies on a platform of affordable innovation. Biocon's strategic licensing partnerships provide market penetration and global access to deliver breakthrough therapeutics to millions of patients the world over.

Visit us at www.biocon.com

For further information contact:

Paula Sengupta

Biocon Limited
Tel: +91 80 2808 2808
Fax: +91 80 2852 3423
Email: paula.sengupta@biocon.com

Sonia Sharma

Brodeur India
Tel: +91 80 4042 9047
Fax: +91 80 4042 9100
Email: ssharma@brodeurindia.com



Press Release - 4

Biocon Limited and Amylin Pharmaceuticals Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid

Program will Focus on the Potential Treatment of Diabetes

Bangalore, India and San Diego, CA – September 11, 2009 –Biocon, Limited (NSE: BIOCON) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity.

Under the terms of the Development and Commercialization Agreement, Amylin will provide expertise in peptide hormone development, particularly in the area of phybrid technology, as well as metabolic disease therapeutics. Biocon will utilize its expertise in recombinant microbial expression to manufacture the compound and also leverage its experience in pre-clinical and clinical development of diabetes products.

"This agreement fully leverages the synergistic capabilities of the two companies," said Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon, Ltd. "Amylin's knowledge of peptide therapeutics and their leadership in the diabetes market, paired with Biocon's capabilities in process development, manufacturing and clinical development, provides this global program with the potential to effectively bring a novel therapy to patients living with diabetes."

"This program could unleash the potential of cutting-edge peptide science to transform the lives of patients with diabetes," said Daniel M. Bradbury, President and Chief Executive Officer, Amylin Pharmaceuticals. "We are pleased to work with Biocon, a biologics innovator and world-class manufacturing expert, and look forward to collaborating with them on this exciting program."

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.



About Biocon Limited

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Together with its group companies, Biocon forms a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research which deliver products and solutions to partners and customers across the globe. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, Biocon offers therapies on a platform of affordable innovation. Biocon has a strong focus in diabetes having launched the world's first recombinant human insulin, INSUGEN®, using a pichia based expression system in 2004 and recombinant glargine, BASALOG®, in 2009. In the oncology segment, Biocon launched India's first indigenously produced novel monoclonal antibody BIOMAB EGFR®. Biocon received the 2009 BioSingapore Asia Pacific Biotechnology Award for Best Listed Company in the region. For more information, visit www.biocon.com

Amylin Forward-Looking Statements

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number of risks and uncertainties, including that the hybrid program mentioned in this press release will not produce the results we expect, our clinical trials may not start when planned and/or confirm previous results; our preclinical studies may not be predictive; our product candidates may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.

Biocon Forward-Looking Statements

Certain statements in this release concerning Biocon's future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



Media Contacts:

Amylin – Anne Erickson

(858) 754-4443 office

(858) 349-3195 cell

anne.erickson@amylin.com

Biocon – Paula Sengupta

+91 (80) 2808 2225 office

+91 98455 42838 cell

paula.sengupta@biocon.com

###